ALEX study: updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer


The ALEX study has demonstrated significantly improved progression-free survival ( PFS ) with Alectinib ( Alecensa ) versus Crizotinib ( Xalkori ) in treatment-naive ALK-positive non-small-cell lung cancer ( NSCLC ) at the primary data cut-off ( 9 February 2017 ).

Researchers have reported mature progression-free survival ( cut-off: 30 November 2018 ) and overall survival ( OS ) data up to 5 years ( cut-off: 29 November 2019 ).

Patients with stage III/IV ALK-positive NSCLC were randomized to receive twice-daily Alectinib 600 mg ( n = 152 ) or Crizotinib 250 mg ( n = 151 ) until disease progression, toxicity, withdrawal or death.

Primary end point was investigator-assessed progression-free survival. Secondary end points included objective response rate, overall survival and safety.

Mature PFS data have shown significantly prolonged investigator-assessed PFS with Alectinib [ hazard ratio ( HR ) 0.43, 95% confidence interval ( CI ) 0.32-0.58; median PFS 34.8 versus 10.9 months Crizotinib ].

Median duration of OS follow-up was: 48.2 months Alectinib, 23.3 months Crizotinib.
OS data remain immature ( 37% of events ).
Median OS was not reached with Alectinib versus 57.4 months with Crizotinib ( stratified HR 0.67, 95% CI 0.46-0.98 ).

The 5-year OS rate was 62.5% ( 95% CI 54.3-70.8 ) with Alectinib and 45.5% ( 95% CI 33.6-57.4 ) with Crizotinib, with 34.9% and 8.6% of patients still on study treatment, respectively.

The OS benefit of Alectinib was seen in patients with central nervous system metastases at baseline [ HR 0.58 ( 95% CI 0.34-1.00 ) ] and those without [ HR 0.76 ( 95% CI 0.45-1.26 ) ].

Median treatment duration was longer with Alectinib ( 28.1 versus 10.8 months ), and no new safety signals were observed.

In conclusion, mature PFS data from ALEX have confirmed significant improvement in progression-free survival for Alectinib over Crizotinib in ALK-positive NSCLC.
OS data remain immature, with a higher 5-year OS rate with Alectinib versus Crizotinib.
This is the first global randomized study to show clinically meaningful improvement in overall survival for a next-generation tyrosine kinase inhibitor versus Crizotinib in treatment-naive ALK-positive non-small-cell lung cancer. ( Xagena )

T Mok et al, Ann Oncol 2020; 31: 1056-1064

XagenaMedicine_2020



Indietro

Altri articoli

Data from the five-year analysis featuring extended follow-up from the phase III COMBI-AD study have confirmed that 12 months of...


There has been an only indirect comparison between Pembrolizumab ( Keytruda ) and Pembrolizumab plus chemotherapy in patients with non-small...


The aim of neo-adjuvant therapy in locally advanced or oligometastatic melanoma is to facilitate radical resection, improve outcomes and undertake...


In the absence of effective vaccines and with limited therapeutic options, convalescent plasma is being collected across the globe for...


The mRNA-1273 vaccine for SARS-CoV-2 is tolerable and immunogenic in older adults. Data on prolonged immunogenicity and effectiveness in preventing severe...


The European Commission ( EC ) has granted conditional marketing authorization to Ayvakyt ( Avapritinib ) as a monotherapy for...


The U.S. Food and Drug Administration ( FDA ) has approved Gallium 68 PSMA-11 ( Ga 68 PSMA-11 ), the...


The FDA ( U.S. Food and Drug Administration ) has approved Ayvakit ( Avapritinib ) for the treatment of adults...


The European Commission ( EC ) has granted marketing authorisation for the expanded use of Erleada ( Apalutamide ) to...